Towards evidence-based use of serum tumour marker requests: An audit of use in a tertiary hospital

Internal Medicine Journal

Volumn 34, Issue 9-10, 2004, Pages 545-550

  Loi, Sherene ^a,b   Haydon, A M M ^a   Shapiro, J ^a   Schwarz, M A ^a   Schneider, H G ^a  

^a ALFRED HOSPITAL   (Australia)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

AFP; CA 15 3; CA 19 9; CA 124; CEA; Guidelines; Tumour markers

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; EVIDENCE BASED MEDICINE; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL SPECIALIST; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ALPHA-FETOPROTEINS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CARCINOEMBRYONIC ANTIGEN; CLINICAL CHEMISTRY TESTS; CROSS-SECTIONAL STUDIES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 8344232230     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2004.00671.x     Document Type: Article

References (22)

1. Bast RC Jr, Ravdin P, Hayes DF et al. American Society of Clinical Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-78.
2. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
3. Rustin GJ, The clinical value of tumour markers in the management of ovarian cancer. Ann Clin Biochem 1996; 33: 284-9.
4. Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996; 78: 977-85.
5. Bruinvels DJ, Stiggelbout AM, Kievit J, van Houwelingen HC, Habbema JD, van de Velde CJ. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994; 219: 174-82.
6. Wolmark N, Fisher B, Wieand HS et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 1984; 199: 375-82.
7. Makar AP, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992; 79: 1002-10.
8. Allen-Mersh TG, Kemeny N, Niedzwiecki D, Shurgot B, Daly JM. Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut 1987; 28: 1625-9.
9. Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001; 19: 4054-7.
10. Ward U, Primrose JN, Finan PJ et al. The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 1993; 67: 1132-5.
11. Chau I, Allen M, Cunningham D et al. The value of routine carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2004; 22: 1420-29.
12. Chu DZ, Erickson CA, Russell MP et al. Prognostic significance of carcinoembryonic antigen in colorectal carcinoma. Serum levels before and after resection and before recurrence. Arch Surg 1991; 126: 314-6.
13. Colomer R, Ruibal A, Genolla J, Salvador L. Circulating CA 15-3 antigen levels in non-mammary malignancies. Br J Cancer 1989; 59: 283-6.
14. Trigo JM, Tabernero JM, Paz-Ares L et al. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 2000; 88: 162-8.
15. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000; 82: 1535-8.
16. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273-8.
17. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997; 349: 485-9.
18. Rhodes JM. Usefulness of novel tumour markers. Ann Oncol 1999; 10: 118-21.
19. Scheuer L, Kauff N, Robson M et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20: 1260-8.
20. Ueno H, Okada S, Okusaka T, Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000; 59: 296-301.
21. Bac DJ, Kok TC, van der Gaast A, Splinter TA. Evaluation of CA 19-9 serum levels for monitoring disease activity during chemotherapy of pancreatic adenocarcinoma. J Cancer Res Clin Oncol 1991; 117: 263-5.
22. Johnson PJ. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J Gastroenterol Hepatol 1999; 14 (Suppl): S32-6.